Via EFS Web Date of Deposit: January 26, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ofer MANDELBOIM et al Attorney. Dkt. No.: 2488.033

Serial No.: 10/562,735 Examiner: HAMUD, Fozia M.

Filed: May 19, 2006 Group Art Unit: 1647

Title: FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED

AND TUMOR CELLS

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIRMENT UNDER 37 C.F.R. §1.142

Dear Sir:

This is in response to the Office Action mailed October 24, 2008, in connection with the above-identified U.S. patent application. In light of a request for a two-month extension of time and fee therefore enclosed herewith, a response is due by January 24, 2009; that being a Saturday, this response is timely filed.

Claims 1-48 were presented at the time of filing; claims 1-27 and 34-48 are currently pending in the application. The Action of October 24, 2008 requires election under 35 U.S.C. §121 between six groups of claims:

Group I – (claims 1-11, 20-27 and 47-48), drawn to an isolated peptide fragment comprising NKp46 receptor, a linker peptide, classified in class 530, subclass 350.

Group II – (claims 1-3, 12-19 and 20-27), drawn to an isolated peptide fragment comprising NKp44 receptor, a linker peptide, classified in class 530, subclass 350.

Group III – (claims 34-37), drawn to a method for treating a viral disease by administering a peptide, classified in class 514, subclass 12

Attorney Docket No.: 2488.033 Page 2 of 2

Group IV – (claims 38-39), drawn to a method for treating a malignant disease by administering a peptide, classified in class 514, subclass 12.

Group V – (claims 40-42), drawn to a monoclonal antibody specific for NKp46 peptide and a method of using said antibody, classified in class 530, subclass 388.1.

 $Group\ VI-(claims\ 43-46),\ drawn\ to\ a\ method\ of\ using\ a\ monoclonal\ antibody,$ classified in class 424, subclass 145.1.

Applicants hereby elect the claims of Group I (claims 1-11, 20-27, and 47-48), drawn to an isolated peptide fragment comprising NKp46 receptor, a linker peptide, classified in class 530, subclass 350. The election is made without traverse and without prejudice to Applicants' right to pursue the subject matter of the non-elected claims in one or more additional applications.

Respectfully submitted,

Kathy Smith Dias Attorney for Applicants

Registration No.: 41,707

Dated: January 26, 2009

Address for Correspondence: Heslin Rothenberg Farley & Mesiti P.C. 5 Columbia Circle

Albany, NY 12203 Tel: 518-452-5600 Fax: 518-452-5579